SOPHiA GENETICS SA (SOPH)
After hours:
| Previous Close | 2.8000 |
| Open | 2.8000 |
| Bid | 3.1700 x 1000 |
| Ask | 3.3000 x 1800 |
| Day's Range | 2.8000 - 3.4900 |
| 52 Week Range | 2.1600 - 19.8000 |
| Volume | |
| Avg. Volume | 103,256 |
| Market Cap | 206.446M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- CNW Group
SOPHiA GENETICS Publishes Results of 2022 Annual General Meeting
SOPHiA GENETICS SA (Nasdaq: SOPH) ("the Company"), is pleased to announce the Annual General Meeting ("the Meeting") was held at the Company's headquarters, rue du Centre 172, 1025 St-Sulpice, VD, Switzerland, earlier today at 2:00 p.m. CET (8:00 a.m. EDT).
- GlobeNewswire
SOPHiA GENETICS Reports Financial Results for the First Quarter of Fiscal 2022
Steady Start to 2022; FY 2022 Constant Currency Revenue Growth Guidance ReaffirmedBOSTON, United States and LAUSANNE, Switzerland, May 10, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2022. Recent Highlights Revenue for the first quarter of 2022 was $10.9 million, representing year-over-year revenue growth of 21%Constant currency revenue growth excluding COVID-19-related revenu
- CNW Group
SOPHiA GENETICS Announces Nomination of Jean-Michel Cosséry to Board of Directors
SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, today announced the nomination of Jean-Michel Cosséry to its Board of Directors. The Board of Directors will propose the appointment of Mr. Cosséry as a member of the Board of Directors and a member of the Compensation Committee to the Annual General Meeting of Shareholders of SOPHiA GENETICS SA, to convene on June 15, 2022.
